Results 211 to 220 of about 120,225 (354)

Revisiting the nature and pharmacodynamics of tacrolimus metabolites

Pharmacological Research
The toxicity of tacrolimus metabolites and their potential pharmacodynamic (PD) interactions with tacrolimus might respectively explain the surprising combination of higher toxicity and lower efficacy of tacrolimus despite normal blood concentrations ...
Rudy Mevizou, Hassan Aouad, François-Ludovic Sauvage, Hélène Arnion, Emilie Pinault, Jean-Sébastien Bernard, Gildas Bertho, Nicolas Giraud, Rodolphe Alves de Sousa, Adolfo Lopez-Noriega, Florent Di Meo, Mélanie Campana, Pierre Marquet   +12 more
doaj  

Decreasing the Risk of Early Sub-Therapeutic Tacrolimus Troughs on Short-Term Outcomes in Low-Moderate Risk Kidney Transplant Recipients Receiving Rabbit Anti-Thymocyte Globulin Induction. [PDF]

Clin Transplant
Liu X, Trofe-Clark J, Sawinski D, Steiner B, Sharma S, Witek S, Fallah T, Norris M, Sammons C, Malat G.   +9 more
europepmc   +1 more source

ORAL TACROLIMUS TREATMENT OF SEVERE COLITIS IN CHILDREN: LONG-TERM FOLLOWUP

, 1998
Athos Bousvaros, Barbara S. Kirschner, Steven L. Werlin, Lorraine Parker-Hartigan, F Daum, Katherine Freeman, J P Balint, Ross S. Kendall, Alice S. Day, A M Griffiths, George Ferry, Alan M. Leichtner   +11 more
openalex   +1 more source

Real‐World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study

Alimentary Pharmacology &Therapeutics, EarlyView.
This real‐world multicenter study assessed the short‐term effectiveness and safety of mirikizumab induction therapy in ulcerative colitis patients. Among 52 patients, the median partial Mayo score significantly decreased from week 0 to 12, and 44.2% achieved clinical remission, with no treatment‐related discontinuations or deaths.
Yasuhiro Takagi, Toshiyuki Sato, Takanori Nishiguchi, Akira Nogami, Masataka Igeta, Soichi Yagi, Maiko Ikenouchi, Mikio Kawai, Koji Kamikozuru, Yoko Yokoyama, Toshihiko Tomita, Hirokazu Fukui, Masayuki Fukata, Taku Kobayashi, Shinichiro Shinzaki   +14 more
wiley   +1 more source

Telitacicept and Tacrolimus Synergy in Managing Refractory Primary Membranous Nephropathy: Case Insights. [PDF]

Am J Case Rep
Huang R, Yin Y, Zhao Z, Dong X, Chen C, Lin H, Tao Y, Peng S, Wen S, Li B, Wu Q, Li S, Lin T, Dai H, Wen F, Li Z, Xu L, Ma J, Liu S, Feng Z.   +19 more
europepmc   +1 more source

Prolongation of canine renal allograft survival by combining tacrolimus with antimetabolic agents [PDF]

, 1997
A. Urakami, M.B. Jin, N. Ishizaki, Platz, S. Todo, T. Shimamura, T. Suzuki, T.E. Starzl, Tanabe, Todo, V.M. Subbotin, Y. Zhu   +11 more
core   +1 more source

Tacrolimus Ointment does not Affect Collagen Synthesis: Results of a Single-Center Randomized Trial

, 1998
Sakari Reitamo, Jonna Rissanen, Anita Remitz, Håkan Granlund, Pekka Erkko, Pekka Autio, Antti I. Lauerma, Peter Elg   +7 more
openalex   +1 more source

Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials [PDF]

, 1999
Greg Knoll, Richard Bell
openalex   +1 more source

Therapeutic drug monitoring of tacrolimus after kidney transplantation: trough concentration or area under curve‐based monitoring?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Measurement of pre‐dose tacrolimus concentrations, also referred to as trough concentrations or C0 (in this paper the term C0 will be used), is the most frequently used parameter for therapeutic drug monitoring in patients after solid organ transplantation. C0 is relatively easy to obtain, and can be combined with other lab tests.
Teun van Gelder, Armin Gelinck, Soufian Meziyerh, Aiko P. J. de Vries, Dirk Jan A. R. Moes   +4 more
wiley   +1 more source

Tacrolimus versus cyclosporine immunosuppression in lung transplantation: a systematic review and meta-analysis. [PDF]

BMJ Open Respir Res
Pitre T, Gurupatham S, Desai K, Binnie M, Martinu T, Juvet S, Zeraatkar D.   +6 more
europepmc   +1 more source